title: [Agranulocytosis induced by dapsone prescribed for dermatitis herpetiformis].
abstract: BACKGROUND
  Dapsone is a drug widely prescribed in dermatology. It can lead to undesirable side effects including hematologic disorders.
  
  
  METHODS
  A patient with dermatitis herpetiformis was treated with dapsone. Agranulocytosis developed 6 weeks later and was revealed by fever and pneumonia which resolved under antibiotics. The agranulocytosis regressed without specific treatment after drug withdrawal. Blood counts returned to normal 2 weeks later.
  
  
  CONCLUSIONS
  Dapsone-induced agranulocytosis is in common (1/10,000 to 1/20,000). The drug is widely prescribed, particularly for leprosy. Nevertheless, when dapsone is prescribed for dermatitis herpetiformis, the risk of agranulocytosis increases 25-fold reaching 1/400. The indication for dapsone must always made carefully, with surveillance of the blood counts every 15 days during the first 3 months of treatment for dermatitis herpetiformis.
authors: Service de Dermatologie, CHU Trousseau, Tours.
authors: L
authors: L
authors: Machet
authors: A
authors: A
authors: Callens
authors: E
authors: E
authors: Mercier
authors: S
authors: S
authors: Gargot
authors: G
authors: G
authors: Lorette
authors: L
authors: L
authors: Vaillant
mesh_terms: D000380:Agranulocytosis / Q000139:chemically induced*; D003622:Dapsone / Q000009:adverse effects* / Q000627:therapeutic use; D003874:Dermatitis Herpetiformis / Q000188:drug therapy*; D005334:Fever / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D003622:Dapsone
vernacular_title: Agranulocytose induite par la dapsone prescrite pour une dermatite herpétiforme.